These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8270976)

  • 1. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.
    Murray JL; Cunningham JE; Brewer H; Mujoo K; Zukiwski AA; Podoloff DA; Kasi LP; Bhadkamkar V; Fritsche HA; Benjamin RS
    J Clin Oncol; 1994 Jan; 12(1):184-93. PubMed ID: 8270976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma.
    Saleh MN; Khazaeli MB; Wheeler RH; Dropcho E; Liu T; Urist M; Miller DM; Lawson S; Dixon P; Russell CH
    Cancer Res; 1992 Aug; 52(16):4342-7. PubMed ID: 1643631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.
    Yu AL; Uttenreuther-Fischer MM; Huang CS; Tsui CC; Gillies SD; Reisfeld RA; Kung FH
    J Clin Oncol; 1998 Jun; 16(6):2169-80. PubMed ID: 9626218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
    Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
    Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients.
    Uttenreuther-Fischer MM; Huang CS; Reisfeld RA; Yu AL
    Cancer Immunol Immunother; 1995 Jul; 41(1):29-36. PubMed ID: 7641217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
    Frost JD; Hank JA; Reaman GH; Frierdich S; Seeger RC; Gan J; Anderson PM; Ettinger LJ; Cairo MS; Blazar BR; Krailo MD; Matthay KK; Reisfeld RA; Sondel PM
    Cancer; 1997 Jul; 80(2):317-33. PubMed ID: 9217046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
    Cheung NK; Lazarus H; Miraldi FD; Abramowsky CR; Kallick S; Saarinen UM; Spitzer T; Strandjord SE; Coccia PF; Berger NA
    J Clin Oncol; 1987 Sep; 5(9):1430-40. PubMed ID: 3625258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
    J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
    Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen.
    Saleh MN; Stapleton JD; Khazaeli MB; LoBuglio AF
    J Immunol; 1993 Sep; 151(6):3390-8. PubMed ID: 8376782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis and optimization of interactions between peptides mimicking the GD2 ganglioside and the monoclonal antibody 14G2a.
    Horwacik I; Kurciński M; Bzowska M; Kowalczyk AK; Czaplicki D; Koliński A; Rokita H
    Int J Mol Med; 2011 Jul; 28(1):47-57. PubMed ID: 21455557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.
    Saleh MN; Khazaeli MB; Wheeler RH; Allen L; Tilden AB; Grizzle W; Reisfeld RA; Yu AL; Gillies SD; LoBuglio AF
    Hum Antibodies Hybridomas; 1992 Jan; 3(1):19-24. PubMed ID: 1576319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.
    Horwacik I; Rokita H
    Int J Oncol; 2017 May; 50(5):1899-1914. PubMed ID: 28393238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.
    Czuczman MS; Straus DJ; Divgi CR; Graham M; Garin-Chesa P; Finn R; Myers J; Old LJ; Larson SM; Scheinberg DA
    J Clin Oncol; 1993 Oct; 11(10):2021-9. PubMed ID: 8410126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
    Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM
    Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells.
    Durbas M; Pabisz P; Wawak K; Wiśniewska A; Boratyn E; Nowak I; Horwacik I; Woźnicka O; Rokita H
    Apoptosis; 2018 Oct; 23(9-10):492-511. PubMed ID: 30027525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
    Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
    Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.
    Scott AM; Lee FT; Hopkins W; Cebon JS; Wheatley JM; Liu Z; Smyth FE; Murone C; Sturrock S; MacGregor D; Hanai N; Inoue K; Yamasaki M; Brechbiel MW; Davis ID; Murphy R; Hannah A; Lim-Joon M; Chan T; Chong G; Ritter G; Hoffman EW; Burgess AW; Old LJ
    J Clin Oncol; 2001 Oct; 19(19):3976-87. PubMed ID: 11579119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients.
    Uttenreuther-Fischer MM; Huang CS; Yu AL
    Cancer Immunol Immunother; 1995 Dec; 41(6):331-8. PubMed ID: 8635190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.
    Saleh MN; Khazaeli MB; Grizzle WE; Wheeler RH; Lawson S; Liu T; Russel C; Meredith R; Schlom J; LoBuglio AF
    Cancer Res; 1993 Oct; 53(19):4555-62. PubMed ID: 8402627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.